Smyd3-mediated immuno-modulation in HPV-negative head and neck squamous cell carcinoma mouse models.

Cell biology Immunology Microenvironment

Journal

iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038

Informations de publication

Date de publication:
20 Sep 2024
Historique:
received: 13 06 2024
revised: 04 07 2024
accepted: 28 08 2024
medline: 23 9 2024
pubmed: 23 9 2024
entrez: 23 9 2024
Statut: epublish

Résumé

SET and MYND-domain containing protein 3 (SMYD3) mediates epigenetic repression of type I IFN response genes in human papillomavirus (HPV)-negative HNSCC cells, and Smyd3 depletion using anti-sense oligonucleotides (ASOs) increases the sensitivity of syngeneic mouse oral carcinoma (MOC1) models to anti-PD-1 therapy. In this study, we utilized single-cell RNA-seq of MOC1 tumors treated with Smyd3 ASOs and found enrichment of type I IFN response pathways in cancer cells, a shift of CD8

Identifiants

DOI: 10.1016/j.isci.2024.110854 PMID: 39310755 PMC: PMC11416682
pubmed: 39310755
doi: 10.1016/j.isci.2024.110854
pii: S2589-0042(24)02079-0
pmc: PMC11416682
doi:

Types de publication

Journal Article

Langues

eng

Pagination

110854

Déclaration de conflit d'intérêts

Xiaolin Luo was an employee of Ionis Pharmaceuticals Inc during this study. The other authors declare no competing interests.

Auteurs

Daniel E Tsai (DE)

Thoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.

Alexei Lovanov (A)

Collaborative Bioinformatics Resource (CCBR), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD 20892, USA.
Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD 20892, USA.

Abdalla Abdelmaksoud (A)

Collaborative Bioinformatics Resource (CCBR), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD 20892, USA.
Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD 20892, USA.

Jawad Akhtar (J)

Thoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.

Mohd Saleem Dar (MS)

Thoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.

Marie Luff (M)

Thoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.

Katherine McKinnon (K)

Center for Cancer Research Vaccine Branch Flow Cytometry Core, National Cancer Institute, Bethesda, MD 20892, USA.

Sohyoung Kim (S)

Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, Bethesda, MD 20852, USA.

Yvette Robbins (Y)

Head and Neck Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20852, USA.

Angel Huynh (A)

Head and Neck Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20852, USA.

Madhavi Murali (M)

Thoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.

Benjamin Bernard (B)

Thoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.

Andrew Sinkoe (A)

Center for Immuno-Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20852, USA.

Xiaolin Luo (X)

Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010, USA.

Karim B (K)

Molecular Histopathology Laboratory, National Institutes of Health, Frederick, MD 21702, USA.

Clint T Allen (CT)

Head and Neck Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20852, USA.

Vassiliki Saloura (V)

Thoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.

Classifications MeSH